Management Of Prostate Cancer

This book, now in an extensively revised second edition, provides an exhaustive review of the state of the art in the management of prostate cancer, from screening to treatment, with emphasis on a multidisciplinary approach. The editors are very excited about the outstanding new or updated contributions from the different expert authors. The opening chapters address basic aspects including epidemiology, pathology, biology, genetics, and chemoprevention. The role of individual and mass screening is carefully appraised, and extensive attention is devoted to diagnosis and clinical work-up by means of recently implemented investigations such as multiparametric MRI and choline PET-CT. The use of active surveillance is examined in detail. Subsequent chapters discuss the different therapies that may be employed: open and minimally invasive, including robot-assisted, radical prostatectomy, the various forms of radiation treatment, high-intensity focused ultrasound, cryotherapy, hormonal manipulations, chemotherapy, targeted therapies, and immunotherapy. Up-to-date results from practice-changing phase III randomized clinical trials are included and special insights are provided into the interpretation of results and the patient’s perspective.

Although much progress has been made in the four years since the first edition of Management of Prostate Cancer, prostate cancer remains a significant biological, me- cal, and personal challenge for millions of men. In this interval, some important trends and observations have emerged that represent real progress in the field and which will shape the direction of clinical practice and research in the next 5–10 years. These obs- vations include: (1) a decline in prostate-related cancer mortality in the United States, likely owing to a combination of factors including screening, more aggressive and earlier therapy, and improvements in specific therapies; (2) a significant downward pathological stage migration, so that an individual’s chance of cure for a given stage, grade, and PSA is better now than it was early in the PSA era, even without associated improvements in individual therapies; (3) the recognition of new PSA isoforms that may refine screening strategies; (4) several randomized, phase III clinical trials demonstrating survival adv- tages of one form of therapy over another in selected populations (external beam rad- therapy with adjuvant hormones vs radiotherapy alone, radical prostatectomy vs observation); (5) a focus on the biology of bone and bone metastasis, and new agents that reduce skeletal-related events and which may inhibit the growth of new metastases; (6) second-generation anti-PSMA antibodies with improved potential for imaging and therapy; (7) the development and widespread adoption of nomograms that assist in cli- cal decision-making for individual patients; (8) the identification of new genes that

Teaches patients with prostate cancer and their loved ones strategies for how to live better with the questions and challenges that arise with this diagnosis.Over 200,000 men in the United States are diagnosed with prostate cancer every year. How they medically combat this disease is up to their medical teams and the latest research. But how they psychologically combat the worry, practical concerns, and all of the changes in their lives? It's up to theindividual himself, as well as family and caregivers, and it is an equally important component in the patient's recovery. Dr. Andrew J. Roth, a psychiatrist who specializes in psychological support for cancer patients, provides the emotional skills and strategies necessary to healthfully deal withthe challenges that a prostate cancer diagnosis brings to daily life. These tools, which Roth terms "Emotional Judo," will also help healthcare givers to provide improved support for their patients and families. For the last twenty years, Dr. Roth has served as the Attending Psychiatrist of theMemorial Sloan Kettering Cancer Center and has helped members of oncology treatment teams practice the best ways to deal with patients' emotional needs.Dr. Roth helps patients at all stages of the disease learn the best ways to accept and adapt to the consequences of their cancer treatment, including the physical complications of urinary, erectile or bowel dysfunction, fatigue, hot flashes, and the demoralizing recurrence of disease aftertreatment. While there are a number of good books that touch on the diagnostic and treatment processes from beginning to end, Dr. Roth's readable and relevant book is the first to focus on the emotional implications of these physiological symptoms and life changes. By focusing on a specificreadership (men with prostate cancer and their loved ones) rather than a broader group, Dr. Roth offers the most effective and tailored tools for coping with any and all aspects of the disease.

This textbook summarizes the state of the art in the management of locally advanced and metastatic prostate cancer with the aim of providing the knowledge required for optimal treatment decision making in individual cases. Readers will find comprehensive coverage of the latest developments in surgery, radiotherapy, androgen deprivation therapy (ADT), chemotherapy, and immunotherapy. The role of the hormonal therapies abiraterone and enzalutamide and docetaxel-based chemotherapy in castration-resistant prostate cancer and hormone-sensitive metastatic disease is carefully evaluated. Among the other therapies discussed are LHRH agonists and antagonists, cabazitaxel, radium-223, and various novel agents still under clinical trials. The section on surgical approaches addresses, among other topics, the use of robot-assisted radical prostatectomy, pelvic lymphadenectomy, and the benefits of adjuvant and neoadjuvant therapy. The current role of external beam radiotherapy, alone or in combination with ADT and brachytherapy, for locally advanced disease is reviewed. Management of Advanced Prostate Cancer will be a valuable resource for practitioners at all levels of expertise.

This volume maintains the successful Current Multidisciplinary Oncology series format. Section I provides a review of fundamental issues including epidemiology, screening and risk reduction, diagnosis and pathologic characterization, staging, and imaging. There is also a chapter on counseling of the high-risk patient. Section II, Treatment of Localized Disease, provides a thorough review of the range of multidisciplinary management options for these patients including a discussion of quality of life impact. Section III, Treatment of Localized Advanced Disease, provides a detailed review of multimodal (medical, surgical, radiologic) therapies. Section IV, Treatment of Advanced Disease, reviews management courses for metastatic disease including the range of novel and experimental agents likely to have major impact on practice. Throughout the volume the emphasis is on multidisciplinary collaboration and decision-making in the management of the prostate cancer patient.

PROSTATE CANCER 20/20 is a streamlined guide to understanding prostate cancer and its management options to enable the newly-diagnosed patient to make an informed choice. Advances in prostate cancer are reviewed: screening and diagnostic testing refinements; preventive measures; advanced imaging techniques; genetic/genomic testing; active surveillance; technical progress in surgical, radiation and focal therapies; new medications for advanced prostate cancer. In-depth information is provided on sexual and urinary complications of treatments and how they are managed. This book is intended for: · Newly diagnosed patients · Patients who have failed primary treatments · Patients with urinary and sexual side effects · Family members

Prostate cancer is the most common neoplasm in men and its management is very complex, in terms of both diagnosis and treatment. In recent years the value of multidisciplinary management within a prostate cancer unit has been increasingly recognized. Such a multidisciplinary approach within a specialized unit involves a variety of specialists, including urologists, oncologists, radiotherapists, radiologists and pathologists. This book describes in detail the advantages of multidisciplinary management of prostate cancer. It opens by explaining the nature of the required multidisciplinary team and the potential benefits of the prostate cancer unit as a structure for the delivery of specialist multidisciplinary care. Epidemiological aspects favoring multidisciplinary management are described and each element of care within the context of the prostate cancer unit is then discussed; also has been described the role of advanced imaging (Multiparametric MRI) in the management of PCa. Early diagnosis, risk classification, treatment decision making, surgery, radiotherapy, medical therapies and health care support are all fully considered. This book will be informative and enlightening for all who are involved in the management of patients with prostate cancer.

This book provides an exhaustive review of the current state of the art in the management of prostate cancer, from screening to treatment. A particular feature is the emphasis placed on the value of a multidisciplinary approach. The opening chapters address basic aspects including epidemiology, biology, and chemoprevention. The role of individual and mass screening is carefully appraised, and diagnosis, clinical work-up, and the role of active surveillance are discussed in detail. Subsequent chapters are devoted to each of the therapies that may be employed, including open and robotic laparoscopic radical prostatectomy, the various forms of radiation therapy, high-intensity focused ultrasound, cryotherapy, hormonal therapy, and targeted therapies and vaccination. Up-to-date data from clinical trials are included. The editors are members of the EORTC who have coordinated phase III EORTC trials and have worldwide reputations.